Literature DB >> 16596767

Final report of the safety assessment of niacinamide and niacin.

.   

Abstract

Niacinamide (aka nicotinamide) and Niacin (aka nicotinic acid) are heterocyclic aromatic compounds which function in cosmetics primarily as hair and skin conditioning agents. Niacinamide is used in around 30 cosmetic formulations including shampoos, hair tonics, skin moisturizers, and cleansing formulations. Niacin is used in a few similar product types. The concentration of use of Niacinamide varies from a low of 0.0001% in night preparations to a high of 3% in body and hand creams, lotions, powders and sprays. Niacin concentrations of use range from 0.01% in body and hand creams, lotions, powders and sprays to 0.1% in paste masks (mud packs). Both ingredients are accepted for use in cosmetics in Japan and the European Union. Both are GRAS direct food additives and nutrient and/or dietary supplements. Niacinamide may be used in clinical treatment of hypercholesteremia and Niacin in prevention of pellegra and treatment of certain psychological disorders. Both ingredients are readily absorbed from skin, blood, and the intestines and widely distribute throughout the body. Metabolites include N1-methylnicotinamide and N1-methyl-4-pyridone-3-carboxamide. Excretion is primarily through the urinary tract. While Niacinamide is more toxic than Niacin in acute toxicity studies, both are relatively non-toxic. Short-term oral, parenteral, or dermal toxicity studies did not identify significant irreversible effects. Niacinamide, evaluated in an in vitro test to predict ocular irritation, was not an acute ocular hazard. Animal testing of Niacinamide in rabbits in actual formulations produced mostly non-irritant reactions, with only some marginally irritating responses. Skin irritation tests of up to 2.5% Niacinamide in rabbits produced only marginal irritation. Skin sensitization tests of Niacinamide at 5% during induction and 20% during challenge were negative in guinea pigs. Neither cosmetic ingredient was mutagenic in Ames tests, with or without metabolic activation. Niacinamide and Niacin at 2 mg/ml were negative in a chromosome aberration test in Chinese hamster ovary cells, but did produce large structural chromosome aberrations at 3 mg/ml. Niacinamide induced sister chromatid exchanges in Chinese hamster ovary cells, but Niacin did not. Under certain circumstances, Niacinamide can cause an increase in unscheduled DNA synthesis in human lymphocytes treated with UV or a nitrosoguanidine compound. Niacinamide itself was not carcinogenic when administered (1%) in the drinking water of mice. No data on the carcinogenic effect of Niacin were available. Niacinamide can moderate the induction of tumors by established carcinogens. Niacinamide in combination with streptozotocin (a nitrosourea compound) or with heliotrine (a pyrrolizidine alkaloid), produced pancreatic islet tumors. On the other hand, Niacinamide reduced the renal adenomas produced by streptozotocin; and intestinal and bladder tumors induced by a preparation of bracken fern. Niacinamide evaluated in in vitro test systems did affect development, but Niacinamide reduced the reproductive/developmental toxicity of 2-aminonicotinamide-amino-1,3,4-thiadiazole hydrochloride and urethane. Clinical testing of Niacinamide produced no stinging sensation at concentrations up to 10%, use tests produced no irritation at concentrations up to 5%, and a 21-day cumulative irritation test at concentrations up to 5% resulted in no irritancy. Niacinamide was not a sensitizer, nor was it a photosensitizer. The CIR Expert Panel considered that Niacinamide and Niacin are sufficiently similar from a toxicologic standpoint to combine the available data and reach a conclusion on the safety of both as cosmetic ingredients. Overall, these ingredients are non-toxic at levels considerably higher than would be experienced in cosmetic products. Clinical testing confirms that these ingredients are not significant skin irritants, sensitizers or photosensitizers. While certain formulations were marginal to slight ocular irritants, other formulations were not. Niacinamide, while not carcinogenic alone, can modulate the induction of tumors by certain established carcinogens. The Panel noted that the doses in these studies are high relative to the low concentrations at which Niacinamide is used in cosmetic formulations. In neither case (tumor protection or tumor promotion) are these findings considered relevant to the use of Niacinamide at its current low concentrations of use in cosmetics. Both ingredients were considered safe as used in cosmetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596767     DOI: 10.1080/10915810500434183

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  17 in total

1.  Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells.

Authors:  Jing Jin; Kyong Bun Lee; Soo Young Park; Ja-June Jang
Journal:  Virchows Arch       Date:  2011-04-09       Impact factor: 4.064

2.  Role of nicotinamide in DNA damage, mutagenesis, and DNA repair.

Authors:  Devita Surjana; Gary M Halliday; Diona L Damian
Journal:  J Nucleic Acids       Date:  2010-07-25

3.  Administration of nicotinamide does not increase platelet levels in mice.

Authors:  Iwona M Konieczna; Swapna Panuganti; Teresa A DeLuca; E Terry Papoutsakis; Elizabeth A Eklund; William M Miller
Journal:  Blood Cells Mol Dis       Date:  2012-12-21       Impact factor: 3.039

4.  Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer.

Authors:  Johannes Wohlrab; Nikola Bangemann; Anke Kleine-Tebbe; Marc Thill; Sherko Kümmel; Eva-Maria Grischke; Rainer Richter; Sophie Seite; Diana Lüftner
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-08-01

5.  In Situ Gel Formation in Microporated Skin for Enhanced Topical Delivery of Niacinamide.

Authors:  Sonalika Bhattaccharjee; Moritz Beck-Broichsitter; Ajay K Banga
Journal:  Pharmaceutics       Date:  2020-05-21       Impact factor: 6.321

6.  Pharmacokinetics of the SABRE agent 4,6-d2-nicotinamide and also nicotinamide in rats following oral and intravenous administration.

Authors:  Inna V Linnik; Peter J Rayner; Ruth A Stow; Simon B Duckett; Graham M T Cheetham
Journal:  Eur J Pharm Sci       Date:  2019-05-09       Impact factor: 4.384

Review 7.  Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment.

Authors:  Eun Seong Hwang; Seon Beom Song
Journal:  Biomolecules       Date:  2020-04-29

Review 8.  Role of Nicotinamide in Genomic Stability and Skin Cancer Chemoprevention.

Authors:  Luca Fania; Cinzia Mazzanti; Elena Campione; Eleonora Candi; Damiano Abeni; Elena Dellambra
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

9.  Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.

Authors:  Satoshi Kumakura; Emiko Sato; Akiyo Sekimoto; Yamato Hashizume; Shu Yamakage; Mariko Miyazaki; Sadayoshi Ito; Hideo Harigae; Nobuyuki Takahashi
Journal:  Toxins (Basel)       Date:  2021-01-11       Impact factor: 4.546

10.  Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study.

Authors:  Juan Pablo Castanedo-Cazares; Gabryela Lárraga-Piñones; Adriana Ehnis-Pérez; Cornelia Fuentes-Ahumada; Cuauhtemoc Oros-Ovalle; Bruce R Smoller; Bertha Torres-Álvarez
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.